ScarX Therapeutics is commercializing SCX-001, a topical formulation of nefopam intended to reduce hypertrophic post-surgical scarring and improve wound healing. The drug candidate is built on Dr. Benjamin Alman’s discovery that nefopam modulates beta-catenin, a protein associated with excessive dermal scarring; the technology originated at The Hospital for Sick Children (SickKids). The company plans to use its recent financing to complete a Phase I, single-site clinical trial enrolling 24 subjects over 18 months to establish a safety profile and collect secondary observational efficacy signals. ScarX was spun off by MaRS Innovation and SickKids and is led by Dr. Alman (scientific founder and chief science officer) and Stephen Whitehead (president and CEO). Prior to the Series A, the company raised $1.7M in dilutive funding and $1.0M in non-dilutive funding to support lead candidate development and preclinical studies. The company is based in Toronto, Canada.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2016